Immunovant
IMVT
147 hedge funds and large institutions have $1.86B invested in Immunovant in 2020 Q4 according to their latest regulatory filings, with 44 funds opening new positions, 54 increasing their positions, 39 reducing their positions, and 11 closing their positions.
300% more first-time investments, than exits
New positions opened: 44 | Existing positions closed: 11
38% more repeat investments, than reductions
Existing positions increased: 54 | Existing positions reduced: 39
34% more capital invested
Capital invested by funds: $1.39B → $1.86B (+$477M)
28% more funds holding
Funds holding: 115 → 147 (+32)
4.03% less ownership
Funds ownership: 45.23% → 41.2% (-4%)
33% less funds holding in top 10
Funds holding in top 10: 6 → 4 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$58.7M |
| 2 |
Invesco
Atlanta,
Georgia
|
+$40.8M |
| 3 |
State Street
Boston,
Massachusetts
|
+$33.2M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$32.3M |
| 5 |
Goldman Sachs
New York
|
+$30.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$58M |
| 2 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
-$42.1M |
| 3 |
VC
Vivo Capital
Palo Alto,
California
|
-$32.1M |
| 4 |
BI
BVF Inc
San Francisco,
California
|
-$31.6M |
| 5 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
-$15.4M |
IMVT Hedge Fund Activity: Q4 2020 in Review
147 of the 5,676 institutional investors tracked by Wall St. Rank reported a position in Immunovant (IMVT) for Q4 2020, worth a combined $1.86B — up 34% from $1.39B a quarter earlier.
Buyers outnumbered sellers: 44 funds opened new IMVT positions and 11 closed out — a net gain of 33 holders — while 54 added to existing stakes and 39 trimmed.
The largest buyer was BlackRock, adding an estimated $58.7M. The largest seller was Point72 Asset Management, cutting an estimated $58M.
- 147 institutional investors held Immunovant (IMVT) as of Q4 2020, up from 115 in Q3 2020.
- Funds reported $1.86B of Immunovant stock for Q4 2020, up 34% quarter-over-quarter.
- 44 funds opened new Immunovant positions in Q4 2020 and 11 closed out, a net change of +33 holders.
- The largest Immunovant buyer in Q4 2020 was BlackRock, an estimated $58.7M added.
- The largest Immunovant seller in Q4 2020 was Point72 Asset Management, an estimated $58M sold.
Based on aggregated 13F filings for Q4 2020.